Petrylak D P, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C
Department of Medicine, Columbia Presbyterian Medical Center, New York, NY 10032-3789, USA.
Semin Oncol. 1999 Oct;26(5 Suppl 17):28-33.
Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) in men with hormone-refractory prostate cancer is in its early stages. While this combination is promising in terms of efficacy, adverse events associated with estramustine are a concern. Estramustine has been associated with side effects such as nausea, vomiting, edema, and serious vascular events. Reported here are the results of phase I and phase II trials in which 280 mg estramustine was given three times daily on days I to 5 in 21-day treatment cycles with docetaxel at varying doses. Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy. A survival benefit from this combination appears achievable from these early studies. As significant antitumor activity can be achieved with docetaxel alone, future studies need to define the minimal dose of estramustine for this combination.
对患有激素难治性前列腺癌的男性患者，雌莫司汀与多西他赛（泰索帝；罗纳普朗克-罗瑞尔公司，宾夕法尼亚州学院村）联合治疗方案的评估尚处于早期阶段。虽然这种联合用药在疗效方面很有前景，但与雌莫司汀相关的不良事件令人担忧。雌莫司汀与恶心、呕吐、水肿及严重血管事件等副作用有关。本文报告了I期和II期试验结果，在21天的治疗周期中，第1至5天每天3次给予280mg雌莫司汀，并联合不同剂量的多西他赛。目前可评估患者的数据支持这种联合用药在未经化疗的患者以及先前接受过治疗的患者中的疗效。从这些早期研究来看，这种联合用药似乎有望带来生存获益。由于单用多西他赛就能取得显著的抗肿瘤活性，未来研究需要确定这种联合用药中雌莫司汀的最小剂量。
